ASCO Update: Non-Hodgkin’s Lymphoma
This and future reports are written by oncologists from Pacific Shores Medical Group (a large group practice in Long Beach, California). The reports are primarily based on notes taken at the American Society of Clinical Oncology
Rituximab Shows Promise in Treating ITP
February 1st 2002ORLANDO, Florida-Rituximab (Rituxan) shows promise in the treatment of immune thrombocytopenic purpura (ITP), according to two poster presentations at the 43rd Annual Meeting of the American Society of Hematology (ASH). Nichola Cooper, MRCP, fellow, and James B. Bussel, MD, professor of pediatrics, both at Weill Medical College of Cornell University, and Mansoor N. Saleh, MD, professor of medicine at the University of Alabama at Birmingham, reported the results of separate studies investigating the efficacy and toxicity of rituximab in adults with refractory ITP. Rituximab binds to the antigen CD20 and depletes circulating B-lymphocyte cells. "In theory," Dr. Cooper said, "if you get rid of the B cells, it decreases the autoimmune response."
Monoclonal Antibodies Mimic Action of IVIG and Can Inhibit Immune Thrombocytopenia
February 1st 2002TORONTO-Monoclonal antibodies directed against red blood cells can be used to inhibit immune forms of thrombocytopenia, according to the results of studies with mice. These results were reported by Alan H. Lazarus, PhD, assistant professor of medicine, Department of Hematology, St. Michael’s Hospital, University of Toronto.
American Cancer Society Asks $5.69 Billion for NCI
February 1st 2002WASHINGTON-The American Cancer Society (ACS) has offered a 13-point legislative agenda for 2002. The agenda backs President Bush’s request that Congress provide the National Institutes of Health $27.3 billion for fiscal year (FY) 2003, thus completing the doubling of the agency’s budget over 5 years.
Chronic Inflammation and Cancer
February 1st 2002A substantial body of evidence supports the conclusion that chronic inflammation can predispose an individual to cancer, as demonstrated by the association between chronic inflammatory bowel diseases and the increased risk of colon carcinoma. Chronic inflammation is caused by a variety of factors, including bacterial, viral, and parasitic infections, chemical irritants, and nondigestible particles.
ONCC Certification Test Results Are Announced
January 1st 2002PITTSBURGH-The Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.
Rituximab Ups Survival in Aggressive and Indolent NHL
January 1st 2002ORLANDO-Presentations at the 43rd Annual Meeting of the American Society of Hematology (ASH) showed increased survival for patients with aggressive and indolent non-Hodgkin’s lymphoma (NHL) who received the anti-CD20 monoclonal antibody rituximab (Rituxan) in addition to standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone).
ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insert
January 1st 2002SILVER SPRING, Maryland-The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended that the agency amend the labeling of Herceptin (trastuzumab, Genentech) to include a new gene-detection test to identify women with metastatic breast cancer who are likely to benefit from the therapy. The 16-to-0 vote backed adding the PathVysion HER-2 DNA Probe Kit to the labeling. The kit is made by Vysis, Inc., now owned by Abbott Laboratories.
Breast Conservation Increases With On-Site Radiation Unit
January 1st 2002SAN FRANCISCO-The rate of breast-conserving surgery with adjuvant radiation therapy increased at a North Carolina community hospital (Durham Regional) after Duke University Medical Center radiation oncologists opened an on-site clinic. The study results were presented at the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 87).
Moffitt’s Diet Guidelines for Immunocompromised Patients
January 1st 2002SAN DIEGO--The staff at the H. Lee Moffitt Cancer Center in Tampa has initiated new practices that allow immunocompromised patients to eat fresh fruits and vegetables without worrying about bacterial infection, said Linda Rice, RN, OCN, RN III, staff nurse at Moffitt’s Medical Oncology/Hematology unit.
Better Prognosis for Outer Quadrant Breast Cancers
January 1st 2002SAN FRANCISCO-Survival rates are significantly higher for women who have outer quadrant breast cancer, when compared with patients who have an inner quadrant lesion, according to results presented at the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO abstract 198). At 20 years, the improvement in survival for women with outer quadrant lesions ranged from 2.2% to 9.4%, depending on age group.
ODAC Reaffirms Safety of Camptosar Bolus Injections
January 1st 2002SILVER SPRING, Maryland-Due to concerns about the postmarketing safety of the bolus or Saltz regimen of Camptosar (irinotecan, Pharmacia) combined with fluorouracil (5-FU) and leucovorin (IFL) as a first-line treatment for metastatic colorectal cancer, the Food and Drug Administration asked its Oncologic Drugs Advisory Committee (ODAC) to review the issue.
The Future of Bioethics: A Talk With Dr. Linda Emanuel
January 1st 2002In this article (the first of a two-part interview), Linda L. Emanuel, MD, PhD, discusses bioethics. Part I highlights end-of-life care and physician-assisted suicide, while part II, which will appear in an upcoming issue of ONI, focuses on organizational ethics and future issues in bioethics.
HIV Postexposure Prophylaxis Guidelines
January 1st 2002ATLANTA-Health care personnel exposed to HIV should be evaluated within hours (rather than days) after their exposure and should be tested for HIV at baseline (ie, to establish infection status at the time of exposure), according to the latest HIV postexposure prophylaxis (PEP) guidelines from the US Public Health Service [MMWR 50:(RR11):1-42, 2001].
Octaphonic Sound Reduces Distress During Therapy
January 1st 2002SAN DIEGO--Anxiety and other symptoms of distress that occur during radiotherapy and chemotherapy sessions were found to be reduced when patients were exposed to octaphonic sound, according to Sook Kim, RN, BSN, a nurse clinician and charge nurse at M.D. Anderson Cancer Center’s Ambulatory Treatment Center.
Ashcroft Decision on Opioids Is Blow to End-of-Life Care
January 1st 2002ST. LOUIS, Missouri-United States Attorney General John Ashcroft "is putting a spoke in the wheel" of end-of-life care, said Karen Stanley, RN, MSN, AOCN, FAAN. In a decision designed to prevent the implementation of Oregon’s Death
NMDP Launches Minority Cord Blood Recruitment Initiative
January 1st 2002MINNEAPOLIS-Give Life Twice. That’s the message behind a new National Marrow Donor Program (NMDP) pilot project designed to increase the number of minority umbilical cord blood units listed on the NMDP Registry. Patients of minority race and ethnicity are less likely than Caucasians to find a matched donor in the Registry, the NMDP said in a press release. The NMDP’s goal is to collect 2,000 units of cord blood from African-American, Hispanic/Latino, and Asian/Pacific Islander donors.
Concurrent Chemo/Radiotherapy in Oropharynx Cancer
January 1st 2002SAN FRANCISCO-Chemotherapy given concomitantly with radiotherapy improves disease-free survival rates in patients with stages III and IV oropharynx carcinoma, according to final results of the 94-01 GORTEC study. The findings were presented at the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO plenary 2).
Herceptin/DM1 Conjugate Promising in Preclinical Studies
January 1st 2002MIAMI BEACH-Trastuzumab (Herceptin), the monoclonal antibody that blocks HER-2, has been chemically linked to the maytansinoid DM1, a powerful cytotoxic agent that attacks tubulin, resulting in a conjugate that is dramatically more effective
Andrew C. von Eschenbach Appointed New NCI Director
January 1st 2002WASHINGTON-President Bush moved quickly to appoint a new director of the National Cancer Institute, naming Andrew C. von Eschenbach, MD, a professor of urology at The University of Texas M.D. Anderson Cancer Center and a cancer survivor.
Study Seeks to Identify Patients at Risk for Readmission
January 1st 2002SAN DIEGO--Nursing staff at Fox Chase Cancer Center are investigating the factors that put cancer patients at risk for hospital readmission, said Carolyn Weaver, RN, MSN, AOCN, a clinical nurse specialist and patient education coordinator
ACCC Launches New Public Policy Website
January 1st 2002ROCKVILLE, Maryland-The Association of Community Cancer Centers (ACCC) has launched a new website (www.accc-cancer.org/publicpolicy) dedicated to regulatory and legislative issues affecting patients with cancer. The website will assist in the education of patients and their families about public policy that affects cancer care.